Bliss GVS Pharma
Drug Manufacturers - Specialty & Generic · BLISSGVS
Small CapHealthcareMature Stable
Gagan Harsh Sharma
Managing Director · Pragmatic
Company DNA
Founder-Centric
About
Bliss GVS Pharma is a Small Cap company in the Healthcare sector, listed on NSE as BLISSGVS. With a market cap of ₹2K Cr and revenue of ₹802 Cr, it is currently in the Mature Stable phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Strong promoter control and active management involvement define the strategic direction and daily operational focus. Its strategic mandate: Strategic focus should shift to geographic penetration in emerging markets to leverage existing pharmaceutical capabilities.
FAQ
What kind of company is Bliss GVS Pharma?
Bliss GVS Pharma is a Small Cap Healthcare company (BLISSGVS) in the Mature Stable phase with a market cap of ₹2K Cr. It is classified as Founder-Centric in culture.
What is Bliss GVS Pharma's culture and work environment like?
Bliss GVS Pharma has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Strong promoter control and active management involvement define the strategic direction and daily operational focus.
Who leads Bliss GVS Pharma?
Bliss GVS Pharma is led by Gagan Harsh Sharma (Managing Director), a Pragmatic leader with 16 years of experience.
What are Bliss GVS Pharma's financials?
Bliss GVS Pharma reported revenue of ₹802 Cr in FY25 with a 5-year revenue CAGR of 2.8%. Operating margin: 12.2%. Market cap: ₹2K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandValue-Champion
LifecycleMature Stable
Strong promoter control and active management involvement define the strategic direction and daily operational focus.
Mandate
Strategic focus should shift to geographic penetration in emerging markets to leverage existing pharmaceutical capabilities.
Strategic focus should shift to geographic penetration in emerging markets to leverage existing pharmaceutical capabilities.
Financials
Revenue FY25₹802 Cr
PAT FY25₹84 Cr
Rev CAGR 5Y2.8%
OPM12.2%
NPM10.5%
ROE8%
ROCE8.7%
P/E20
Fwd P/E—
P/B1.9
D/E4.5
Mkt Cap₹2K Cr
Promoter62.4%
Institutional6.6%
Similar Culture
Could You Lead Bliss GVS Pharma?
Take the Genome Benchmark →